X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (107) 107
humans (91) 91
male (67) 67
female (62) 62
middle aged (55) 55
adult (50) 50
brain neoplasms - diagnostic imaging (49) 49
aged (44) 44
oncology (44) 44
magnetic resonance imaging (42) 42
radiology, nuclear medicine & medical imaging (42) 42
clinical neurology (40) 40
tyrosine - analogs & derivatives (40) 40
positron-emission tomography (38) 38
glioma (36) 36
positron-emission-tomography (36) 36
glioma - diagnostic imaging (32) 32
brain (31) 31
tumors (31) 31
tyrosine (28) 28
brain-tumors (27) 27
medicine & public health (27) 27
pet (27) 27
positron-emission tomography - methods (27) 27
tomography (27) 27
o--l-tyrosine pet (24) 24
brain cancer (23) 23
brain tumors (23) 23
f-18-fet pet (23) 23
amino acids (22) 22
fet pet (21) 21
diagnosis (20) 20
mri (20) 20
nuclear medicine (20) 20
positron emission (20) 20
positron emission tomography (20) 20
glioblastoma (19) 19
prognosis (19) 19
radiopharmaceuticals (19) 19
c-11-methionine pet (18) 18
patients (18) 18
brain neoplasms - metabolism (17) 17
brain neoplasms - pathology (17) 17
gliomas (17) 17
imaging / radiology (17) 17
adolescent (16) 16
neurology (16) 16
nuclear magnetic resonance--nmr (16) 16
young adult (16) 16
glioma - pathology (15) 15
pet imaging (15) 15
tumor (15) 15
amino acid pet (14) 14
care and treatment (14) 14
chemotherapy (14) 14
medical imaging (14) 14
radiotherapy (14) 14
response assessment (14) 14
retrospective studies (14) 14
surgery (14) 14
treatment outcome (14) 14
glioblastoma - diagnostic imaging (13) 13
radiation necrosis (13) 13
sensitivity and specificity (13) 13
bevacizumab (12) 12
disease progression (12) 12
dynamic f-18-fet pet (12) 12
glioblastoma multiforme (12) 12
high-grade gliomas (12) 12
neuroimaging (12) 12
neurosciences (12) 12
pseudoprogression (12) 12
temozolomide (12) 12
tyrosin (12) 12
tyrosine - metabolism (12) 12
animals (11) 11
brain neoplasms - therapy (11) 11
cancer (11) 11
cardiology (11) 11
child (11) 11
kinetics (11) 11
magnetic resonance imaging - methods (11) 11
malignant glioma (11) 11
orthopedics (11) 11
uptake kinetics (11) 11
usage (11) 11
brain neoplasms - drug therapy (10) 10
cerebral gliomas (10) 10
f-fet pet (10) 10
follow-up studies (10) 10
neoplasm grading (10) 10
pets (10) 10
research (10) 10
brain neoplasms - diagnosis (9) 9
diagnostic systems (9) 9
high-grade glioma (9) 9
phenols (9) 9
radiopharmaceuticals - pharmacokinetics (9) 9
survival (9) 9
abstracts (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 1/2013, Volume 40, Issue 1, pp. 22 - 33
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 03/2018, Volume 45, Issue 3, pp. 443 - 451
PurposeThe molecular features isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion have gained major importance for both glioma typing and prognosis... 
IDH mutation | Glioma | 1p/19q co-deletion | FET pet | Tyrosine | Brain | Typing | Brain tumors | Brain cancer | Positron emission | Parameter sensitivity | Gene deletion | Clonal deletion | Classification | Tomography | Deletion | Diagnostic systems | Mutation | Isocitrate dehydrogenase | Positron emission tomography
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 2015, Volume 42, Issue 5, pp. 685 - 695
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 07/2012, Volume 53, Issue 7, pp. 1048 - 1057
Journal Article
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 05/2017, Volume 58, Issue 5, pp. 700 - 705
Restoration of the blood-brain barrier (BBB) after antiangiogenic therapy of gliomas with bevacizumab may result in a decrease in contrast enhancement on MRI... 
F-FET PET | Evans blue dye | Blood-brain barrier | PET | Glioblastoma | Bevacizumab | blood-brain barrier | RECURRENT GLIOMA | AMINO-ACID PET | VALUABLE DIAGNOSTIC-TOOL | RESPONSE ASSESSMENT | PROGNOSTIC VALUE | UPTAKE KINETICS | F-18-FET PET | glioblastoma | POSITRON-EMISSION-TOMOGRAPHY | NEUROONCOLOGY WORKING GROUP | bevacizumab | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | HIGH-GRADE GLIOMA | Reproducibility of Results | Radiopharmaceuticals - pharmacokinetics | Bevacizumab - administration & dosage | Brain Neoplasms - diagnostic imaging | Capillary Permeability - drug effects | Rats | Male | Positron-Emission Tomography - methods | Blood-Brain Barrier - drug effects | Tyrosine - analogs & derivatives | Brain Neoplasms - metabolism | Glioma - metabolism | Animals | Blood-Brain Barrier - diagnostic imaging | Glioma - diagnostic imaging | Sensitivity and Specificity | Tyrosine - pharmacokinetics | Therapy | Nuclear magnetic resonance--NMR | Brain tumors | Membrane permeability | Fluorescence | Restoration | Neostriatum | Xenografts | Tomography | Tyrosine | Immunodeficiency | Positron emission | Histology | Permeability | Studies | Autoradiography | Magnetic resonance imaging | Antiangiogenics | Influence | Glioblastoma cells | Diagnostic systems | Positron emission tomography | Viability | Tumors | Long-term effects | Index Medicus
Journal Article
Clinical Nuclear Medicine, ISSN 0363-9762, 10/2019, Volume 44, Issue 10, pp. e581 - e582
ABSTRACTA variety of neoplastic and nonneoplastic conditions involve the corpus callosum, which may result in a “butterfly” appearance on conventional MRI.... 
Journal Article
Clinical Nuclear Medicine, ISSN 0363-9762, 10/2019, Volume 44, Issue 10, pp. e581 - e582
A variety of neoplastic and nonneoplastic conditions involve the corpus callosum, which may result in a "butterfly" appearance on conventional MRI. Typically,... 
Index Medicus
Journal Article
Neuro-Oncology, ISSN 1522-8517, 7/2013, Volume 15, Issue 7, pp. 816 - 817
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 2017, Volume 44, Issue 13, pp. 1 - 2265
Purpose Both perfusion-weighted MR imaging (PWI) and O-(2-18F-fluoroethyl)-L-tyrosine PET (18F–FET) provide grading information in cerebral gliomas. The aim of... 
PET/MR imaging | Pwi | Fet pet | Glioma | Grading | PET/MRimaging | Tyrosine | Neuroimaging | Slopes | Brain | Evaluation | Brain tumors | Abnormalities | Positron emission | Inspection | Patients | Maps | Magnetic resonance imaging | Perfusion | Mathematical analysis | Quality | Spots | Tomography | Diagnostic systems | Positron emission tomography
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 03/2019, Volume 46, Issue 3, pp. 540 - 557
Journal Article